Plozasiran
Plozasiran is an siRNA therapy conjugated with GalNAc that targets and degrades apoC-III messenger RNA, leading to reduced levels of apoC-III protein in the liver and serum. By lowering apoC-III, this medication enhances the clearance of triglycerides from the blood. It is being investigated for the treatment of conditions associated with elevated triglycerides, such as hypertriglyceridemia.
Plozasiran is an siRNA therapy that lowers triglycerides by reducing apoC-III protein through RNA interference.
Key facts at a glance
- RxNorm
- 2727175
- Generic
- Plozasiran
- Class
- unclassified
- Brands
- Redemplo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Plozasiran is under investigation for the treatment of hypertriglyceridemia and other metabolic disorders characterized by elevated serum triglyceride levels. It may also be studied in patients with cardiovascular risk associated with high triglyceride levels.
Plozasiran is a small interfering RNA (siRNA) molecule conjugated to GalNAc (N-acetylgalactosamine), which facilitates delivery to hepatocytes. Once inside liver cells, it binds to and degrades apoC-III mRNA through the RNA interference mechanism, preventing translation of the apoC-III protein. Reduced apoC-III protein leads to enhanced lipoprotein lipase activity and increased clearance of triglyceride-rich lipoproteins from the bloodstream.
As an siRNA therapy, plozasiran is administered via injection and works by selectively silencing a specific gene. Clinical trials are ongoing to determine safety, efficacy, and optimal dosing. Patients should be monitored for potential liver effects and changes in lipid profiles. The medication targets hepatic apoC-III production specifically due to GalNAc-mediated uptake.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy